

8 October 2010

Release of Securities from Voluntary Escrow

In accordance with ASX Listing Rule 3.10A, Antisense Therapeutics Limited advises that 18,475,000 fully paid ordinary shares held by Isis Pharmaceuticals Inc (Isis) will be released from voluntary escrow on 22 October 2010.

The shares were issued to the Isis group 12 months ago as consideration for the supply of drug compound for a clinical trial.

Isis are a long term shareholder of Antisense Therapeutics Limited.

Yours faithfully

Phillip Hains
Company Secretary

Antisense Therapeutics Limited (ASX: ANP) is an Australian publicly listed biopharmaceutical drug discovery and development company. Its mission is to create, develop and commercialise antisense pharmaceuticals for large unmet markets. ANP has two drugs in development and two drugs in pre-clinical research. ATL1102 (injection) has successfully completed a Phase II efficacy and safety trial, significantly reducing the number of MRI lesions in patients with multiple sclerosis. ATL1103 is a second-generation antisense drug designed to lower blood IGF-I levels and is entering the clinical stage of development as a potential treatment for growth and vision disorders. ATL1102 (inhaled) is at the pre-clinical research stage as a potential treatment for asthma. ATL1101 is a second-generation antisense drug at the pre-clinical stage being investigated as a potential treatment for prostate cancer.

Contact Information: Website: www.antisense.com.au
Managing Director: Mark Diamond +61 3 9827 8999
Investor Relations: Simon Watkin +61 (0) 413 153272